Literature DB >> 1968417

Effect of the somatostatin analogue SMS 201-995 on faecal fat excretion in acromegaly.

A R McGregor1, W D Troughton, R A Donald, E A Espiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1968417     DOI： 10.1055/s-2007-1004850

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN： 0018-5043            Impact factor:   2.936


× No keyword cloud information.
  4 in total

1.  Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

Authors:  P Chanson; A Leselbaum; J Blumberg; G Schaison
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

Review 2.  Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors:  P N Maton
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

Review 3.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

4.  Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.

Authors:  P J Ho; L D Boyajy; E Greenstein; A L Barkan
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.